Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

KB111

Gene therapy · Gene replacement · developed by Krystal Biotech

Early Phase 1 Most advanced trial
KRYS Developer
1 Registered trials

What is KB111?

KB111 is a replication-defective, non-integrating herpes simplex virus type 1-based vector that encodes full-length human ATP2C1 protein, formulated as a gel for topical application. It is studied in Hailey-Hailey disease, a benign familial skin disease, and other skin lesions.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Gene therapy
Mechanism
Gene replacement
Therapy area
Dermatology
Developer
Krystal Biotech, Inc. (KRYS)
FDA status
Investigational, not approved in the US. Most advanced trial: Early Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07717346 Early Phase 1 Hailey Hailey Disease Recruiting KRYS

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Hailey Hailey DiseaseLesion SkinSkin Diseases

More from Krystal Biotech

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the KRYS page.

Follow KRYS, the company behind KB111

See KRYS's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

KRYS catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.